Halozyme Therapeutics, Inc. $HALO Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 679,563 shares of the biopharmaceutical company’s stock after selling 102,272 shares during the period. Boston Trust Walden Corp’s holdings in Halozyme Therapeutics were worth $43,920,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC increased its holdings in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 124 shares during the last quarter. Larson Financial Group LLC grew its stake in Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares in the last quarter. Harbour Investments Inc. grew its stake in Halozyme Therapeutics by 152.5% in the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 372 shares in the last quarter. Clearstead Advisors LLC grew its stake in Halozyme Therapeutics by 64.8% in the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 331 shares in the last quarter. Finally, Wexford Capital LP acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at approximately $70,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Up 3.2%

Shares of Halozyme Therapeutics stock opened at $79.45 on Friday. Halozyme Therapeutics, Inc. has a 12-month low of $53.33 and a 12-month high of $82.22. The firm has a market capitalization of $9.42 billion, a PE ratio of 28.58, a price-to-earnings-growth ratio of 0.32 and a beta of 0.84. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The stock’s fifty day moving average is $69.18 and its 200-day moving average is $69.35.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The business had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.Halozyme Therapeutics’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same quarter last year, the company posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on HALO. Morgan Stanley decreased their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, June 16th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Finally, UBS Group restated a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $81.60.

Insider Activity

In other news, CEO Helen Torley sold 10,000 shares of the stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $69.07, for a total value of $690,700.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at $53,030,564.60. This represents a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total value of $124,653.75. Following the completion of the sale, the director directly owned 42,044 shares of the company’s stock, valued at approximately $3,225,195.24. This represents a 3.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 82,179 shares of company stock worth $5,687,400 over the last quarter. Corporate insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.